Condition: CLL/SLL · Sponsor: The First Affiliated Hospital with Nanjing Medical University
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
This description comes directly from the study's public registry record.
Huayuan Zhu, MD · 025-58530260 · huayuan.zhu@hotmail.com
Always discuss trial participation with your own doctor first.
| Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital | Nanjin, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508684